Phathom Pharmaceuticals(US:PHAT)2025-06-19 09:05Business & Product Updates - VOQUEZNA prescriptions filled reached over 143,000[9, 21] - Commercial coverage expanded to over 120 million lives[9, 25] - The company successfully completed an equity follow-on, raising $130 million in gross proceeds[9] - Three VOQUEZNA products are approved across three indications[14] Commercial Launch Progress - Filled prescriptions grew significantly in Q3 2024, reaching approximately 69,000, a ~100% increase compared to Q2 2024[20] - Cumulative writers increased to over 12,400 in Q3 2024, a ~70% increase compared to Q2 2024[24] - Over 80% commercial coverage has been established[25] Financial Results - Net revenues for Q3 2024 were $16.4 million[33, 35] - Non-GAAP SG&A expenses were $71.8 million in Q3 2024[37] - Non-GAAP R&D expenses were $7.4 million in Q3 2024[37] - Adjusted net loss for Q3 2024 was $67.85 million, or $1.05 per share[39] - Cash and cash equivalents totaled $334.7 million as of September 30, 2024[40]